Rock Springs Capital Management LP Buys 29,987 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Rock Springs Capital Management LP lifted its stake in Perspective Therapeutics, Inc. (NYSE:CATX) by 7.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 444,383 shares of the company’s stock after acquiring an additional 29,987 shares during the period. Rock Springs Capital Management LP owned approximately 0.66% of Perspective Therapeutics worth $1,418,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. State Street Corp lifted its holdings in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. Nicholson Wealth Management Group LLC grew its position in Perspective Therapeutics by 0.4% in the 4th quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock valued at $5,134,000 after acquiring an additional 7,000 shares during the last quarter. Affinity Asset Advisors LLC raised its position in Perspective Therapeutics by 160.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock valued at $4,147,000 after purchasing an additional 800,000 shares in the last quarter. Geode Capital Management LLC boosted its position in Perspective Therapeutics by 12.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company’s stock valued at $15,546,000 after acquiring an additional 129,654 shares in the last quarter. Finally, Walleye Capital LLC increased its position in Perspective Therapeutics by 2,526.2% during the 4th quarter. Walleye Capital LLC now owns 475,792 shares of the company’s stock valued at $1,518,000 after buying an additional 457,675 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Insider Activity

In related news, Director Robert F. Williamson III bought 38,145 shares of Perspective Therapeutics stock in a transaction that occurred on Monday, March 31st. The stock was purchased at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the acquisition, the director now owns 108,982 shares in the company, valued at $233,221.48. This trade represents a 53.85 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Johan M. Spoor purchased 22,026 shares of the business’s stock in a transaction dated Friday, March 28th. The shares were acquired at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the acquisition, the chief executive officer now owns 59,383 shares of the company’s stock, valued at approximately $133,017.92. The trade was a 58.96 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 115,696 shares of company stock valued at $256,344. Company insiders own 3.52% of the company’s stock.

Perspective Therapeutics Stock Performance

NYSE CATX opened at $1.94 on Monday. Perspective Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $19.05. The business has a 50 day moving average price of $2.39 and a two-hundred day moving average price of $5.00.

Wall Street Analyst Weigh In

A number of research firms recently commented on CATX. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Truist Financial reduced their target price on Perspective Therapeutics from $21.00 to $10.00 and set a “buy” rating for the company in a report on Monday, April 7th. Royal Bank of Canada cut their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, March 27th. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Finally, Scotiabank started coverage on Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Perspective Therapeutics presently has an average rating of “Buy” and a consensus target price of $12.75.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.